Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$7.76

-0.23 (-2.88%)

07:13
11/28/16
11/28
07:13
11/28/16
07:13

Recro Pharma meloxicam Phase III clinical trial achieves primary endpoint

Recro Pharma announced positive results from its second of two Phase III clinical trials evaluating intravenous meloxicam for the treatment of acute postoperative pain. In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference, or SPID, over the first 24 hours, or SPID24, compared to placebo, in patients following abdominoplasty surgery. With the positive data from this study, the company believes this completes the efficacy program for the IV meloxicam New Drug Application, or NDA. In this multicenter, randomized, double-blind, placebo-controlled clinical trial, 219 patients were enrolled and randomly assigned to receive a postoperative regimen of IV meloxicam or placebo in a 1:1 ratio, once every 24 hours. The IV meloxicam treatment arm demonstrated a statistically significant reduction in SPID24 compared to the placebo arm. The study also achieved statistical significance for 10 of the secondary endpoints, including statistically significant differences in SPID12, time to perceptible pain relief, subjects with greater than or equal to 30% improvement at 24 hours, number of times patients required rescue in the first 24 hours after randomization, as well as number of times rescued from 24 to 48 hours, and several other pain relief metrics, compared to placebo. The safety results demonstrated that IV meloxicam was well tolerated with no difference in serious adverse events, or SAEs, related to bleeding for IV meloxicam treated patients versus placebo. There were two additional SAEs observed in the placebo group. The most common adverse events, or AEs, were nausea, headache, vomiting, and dizziness. The incidence of these events was lower than those observed in the placebo group. The majority of AEs were mild in nature and one patient in the placebo group discontinued treatment due to an adverse event of post-procedural bleeding. There were no meaningful differences between treatment groups in vital signs, ECGs or clinical lab assessments.

  • 29

    Nov

REPH Recro Pharma
$7.76

-0.23 (-2.88%)

08/29/16
JANY
08/29/16
INITIATION
JANY
Buy
Recro Pharma initiated with a Buy at Janney Capital
Target $21.
08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
09/16/16
ROTH
09/16/16
INITIATION
Target $24
ROTH
Buy
Recro Pharma initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Recro Pharma with a Buy rating and $24 price target.
10/03/16
BMUR
10/03/16
INITIATION
Target $21
BMUR
Buy
Recro Pharma coverage assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage on Recro Pharma with a Buy rating citing upcoming catalysts and its lead product candidate which could serve as a non-opioid alternative for pain management. Yang placed a $21 price target on Recro Pharma shares, which is reduced from the firm's prior price target of $28.

TODAY'S FREE FLY STORIES

M

Macy's

$32.23

-0.0615 (-0.19%)

15:29
02/22/17
02/22
15:29
02/22/17
15:29
Hot Stocks
S&P cuts Macy's to 'BBB-' from 'BBB', removes from CreditWatch »

S&P Global Ratings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$15.14

0.51 (3.49%)

15:20
02/22/17
02/22
15:20
02/22/17
15:20
Options
Square options imply 11.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TIME

Time Inc.

$19.10

-0.3 (-1.55%)

, MDP

Meredith

15:19
02/22/17
02/22
15:19
02/22/17
15:19
Periodicals
Time Inc only entertaining bids for entire company, NY Post says »

A breakup of Time Inc…

TIME

Time Inc.

$19.10

-0.3 (-1.55%)

MDP

Meredith

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

$NSD

NASDAQ Market Internals

15:17
02/22/17
02/22
15:17
02/22/17
15:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:17
02/22/17
02/22
15:17
02/22/17
15:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPB

Campbell Soup

$59.16

0.21 (0.36%)

, KMB

Kimberly-Clark

$135.98

1.34 (1.00%)

15:16
02/22/17
02/22
15:16
02/22/17
15:16
Periodicals
Campbell Soup, Kimberly-Clark rumored as takeover targets, Kass says »

Doug Kass of TheStreet…

CPB

Campbell Soup

$59.16

0.21 (0.36%)

KMB

Kimberly-Clark

$135.98

1.34 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 19

    Mar

AOLS

Aeolus Pharmaceuticals

$0.19

-0.006 (-3.06%)

15:14
02/22/17
02/22
15:14
02/22/17
15:14
Hot Stocks
Aeolus Pharmaceuticals initiates Phase 1 study of AEOL 10150 »

Aeolus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
02/22/17
02/22
15:10
02/22/17
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SA

Seabridge Gold

$11.35

-0.2 (-1.73%)

15:07
02/22/17
02/22
15:07
02/22/17
15:07
Hot Stocks
Seabridge Gold completes sale of Castle-Blackrock claims to Columbus Gold »

Seabridge Gold reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.33

-0.21 (-3.79%)

15:05
02/22/17
02/22
15:05
02/22/17
15:05
Options
Ocwen options imply 15.4% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AJRD

Aerojet Rocketdyne

$19.17

-0.16 (-0.83%)

, LLL

L-3 Communications

$168.49

-0.31 (-0.18%)

15:02
02/22/17
02/22
15:02
02/22/17
15:02
Hot Stocks
Aerojet Rocketdyne to acquire Coleman Aerospace for $15M in cash »

Aerojet Rocketdyne (AJRD)…

AJRD

Aerojet Rocketdyne

$19.17

-0.16 (-0.83%)

LLL

L-3 Communications

$168.49

-0.31 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DO

Diamond Offshore

$16.84

-0.52 (-3.00%)

15:01
02/22/17
02/22
15:01
02/22/17
15:01
Options
Diamond Offshore draws opening call writing »

Diamond Offshore draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCRA

Vocera

$19.91

-0.035 (-0.18%)

14:59
02/22/17
02/22
14:59
02/22/17
14:59
Conference/Events
Vocera management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 21

    Mar

PCTY

Paylocity

$36.86

0.59 (1.63%)

14:55
02/22/17
02/22
14:55
02/22/17
14:55
Conference/Events
Paylocity management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SCMP

Sucampo

$12.60

0.8 (6.78%)

, NILE

Blue Nile

14:55
02/22/17
02/22
14:55
02/22/17
14:55
Hot Stocks
Sucampo to replace Blue Nile in the S&P 600 as of February 23 open »

Sucampo Pharmaceuticals…

SCMP

Sucampo

$12.60

0.8 (6.78%)

NILE

Blue Nile

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

BPT

BP Prudhoe Bay

$29.68

-0.8716 (-2.85%)

14:53
02/22/17
02/22
14:53
02/22/17
14:53
Periodicals
BP Prudhoe Bay mentioned cautiously in a Seeking Alpha Pro article 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$277.39

5.16 (1.90%)

, GM

General Motors

$37.83

0.02 (0.05%)

14:52
02/22/17
02/22
14:52
02/22/17
14:52
Earnings
On The Fly: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

TSLA

Tesla

$277.39

5.16 (1.90%)

GM

General Motors

$37.83

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

FIT

Fitbit

$5.81

-0.23 (-3.81%)

14:51
02/22/17
02/22
14:51
02/22/17
14:51
Options
Healthy volume in FitBit weekly options ahead of earnings later today »

Healthy volume in FitBit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TSLA

Tesla

$277.39

5.16 (1.90%)

14:50
02/22/17
02/22
14:50
02/22/17
14:50
Options
Tesla options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PM

Philip Morris

$104.33

-0.23 (-0.22%)

14:49
02/22/17
02/22
14:49
02/22/17
14:49
Earnings
Philip Morris raises FY17 EPS view to $4.80-$4.95 from $4.70-$4.85 »

Consensus $4.80. PMI is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBPB

Potbelly

14:46
02/22/17
02/22
14:46
02/22/17
14:46
Conference/Events
Potbelly management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

APA

Apache

$55.25

-0.64 (-1.15%)

, HRL

Hormel Foods

$37.21

-0.39 (-1.04%)

14:44
02/22/17
02/22
14:44
02/22/17
14:44
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

APA

Apache

$55.25

-0.64 (-1.15%)

HRL

Hormel Foods

$37.21

-0.39 (-1.04%)

KSS

Kohl's

$41.28

-0.5 (-1.20%)

PF

Pinnacle Foods

$54.75

-0.49 (-0.89%)

CHK

Chesapeake

$5.97

-0.11 (-1.81%)

CNK

Cinemark

$43.25

0.37 (0.86%)

AMCX

AMC Networks

$57.69

1.86 (3.33%)

W

Wayfair

$41.08

0.82 (2.04%)

SFM

Sprouts Farmers Markets

$19.32

0.2 (1.05%)

TREE

LendingTree

$113.60

0.65 (0.58%)

TXMD

TherapeuticsMD

$5.56

-0.03 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 07

    May

  • 11

    May

TSLA

Tesla

$277.39

5.16 (1.90%)

, HPQ

HP Inc.

$16.15

0.02 (0.12%)

14:44
02/22/17
02/22
14:44
02/22/17
14:44
Earnings
Notable companies reporting after market close »

Notable companies…

TSLA

Tesla

$277.39

5.16 (1.90%)

HPQ

HP Inc.

$16.15

0.02 (0.12%)

CTRP

Ctrip.com

$47.06

1.43 (3.13%)

ETE

Energy Transfer Equity

$18.90

-0.15 (-0.79%)

LB

Labarge

RRC

Range Resources

$30.27

-0.15 (-0.49%)

SQ

Square

$15.10

0.47 (3.21%)

RIG

Transocean

$13.23

-0.245 (-1.82%)

SLCA

U.S. Silica

$59.37

1.27 (2.19%)

JACK

Jack in the Box

$107.37

-0.09 (-0.08%)

CAKE

Cheesecake Factory

$60.67

-1.16 (-1.88%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

FIT

Fitbit

$5.81

-0.23 (-3.81%)

ELGX

Endologix

$6.49

-0.27 (-3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 08

    Mar

  • 21

    Mar

  • 23

    Mar

  • 27

    Mar

  • 17

    Apr

I

Intelsat

$4.48

-0.19 (-4.07%)

14:41
02/22/17
02/22
14:41
02/22/17
14:41
Options
Ambitious call buying in Intelsat as shares drop off 52-week highs »

Ambitious call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TPIV

TapImmune

$4.30

-0.1 (-2.27%)

14:38
02/22/17
02/22
14:38
02/22/17
14:38
Periodicals
TapImmune cancer vaccine efforts highlighted in Fox News affliate report »

Fox News 13 of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.